SpectraCure reported a Q1 2025 net loss of -6.3 MSEK, with cash reserves declining to 8.1 MSEK and a planned rights issue to secure funding for ongoing clinical studies. Key milestones included positive interim clinical results and patent portfolio expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.